Svar Life Science AB ads

From ADA screening to NAb assays—ensure robust immunogenicity data for biologics and advanced therapies. Built for complex studies, regulatory expectations, and clinical programmes. From assay development to clinical sample analysis — partner with us in immunoassays and immune response evaluation.

Looking for a flexible, reliable bioanalytical partner? Reduce risk with a CRO built for transparency, flexibility, high quality and delivery. We provide scalable capacity, transparent processes, and consistent delivery—supporting outsourcing strategies from early development to clinical trials.

Enable confident decision-making with robust biomarker analysis across discovery and clinical phases. Our integrated bioanalytical and biomarker capabilities support translational strategies across discovery and clinical — supporting PK/PD, pharmacology and patient stratification helping you move forward with confidence.

Large molecules, evolving assays, increasing regulatory demands— your bioanalysis partner matters. Partner with a CRO that combines deep expertise, a consultative mindset, and unique capabilities to guide your PK/PD studies—from method development to final analysis.

Growing evidence highlights the role of the complement system in severe and potentially life-threatening immune-mediated reactions to AAV-based gene therapies. Researchers at the forefront of gene therapy development require fit‑for‑purpose tools that can deliver robust immunogenicity assessment, crucial to ensuring the safety and efficacy of these innovative therapies. At Svar Life Science we support scientists with unique AAV Complement Activation solutions, including our new AAV9-induced Complement Activation assay.

Monitoring of complement activation is gaining increasing importance in the assessment of the immune response against AAV-mediated gene therapies. Growing evidence highlights the role of the complement system in severe and potentially life-threatening immune-mediated responses to AAV-based gene therapies, such as thrombotic microangiopathy (TMA). Svar AAV-induced Complement Activation assay is the first and only designed to support safer AAV-mediated gene therapy development by specifically evaluating pathway-independent complement activation and sample-to-sample variability in a human-serum functional assay. Learn how our AAV Immunogenicity Suite of assays can support your research: https://lnkd.in/eE3nYbgS